BreezeBio
Develops genetic medicines enabled by precise, non-viral nanoparticle delivery across tissues
$60MSeries B
Role not disclosedKI
Korea Investment Partners
Activity from announced rounds
Activity in this selectionFeb 28, 2026 · Feb 1, 2026
Korea Investment Partners is the investment manager named in Q-Factor and BreezeBio financing histories.
Recorded funding activity
Q-Factor develops neutral-atom quantum computing. BreezeBio develops genetic medicines using non-viral nanoparticle delivery. The stored Precision Neuroscience relationship remains in draft rather than being published with the investor profile.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $60M 1 disclosed · full round size, not this investor’s share